Get the Stockscreener App
22.90
0.13%
-0.03
After Hours:
23.00
0.10
+0.44%
Caredx Inc stock is traded at $22.90, with a volume of 1.70M.
It is down -0.13% in the last 24 hours and down -25.91% over the past month.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.
See More
Previous Close:
$22.93
Open:
$21.31
24h Volume:
1.70M
Relative Volume:
1.87
Market Cap:
$1.21B
Revenue:
$280.32M
Net Income/Loss:
$-190.28M
P/E Ratio:
-14.68
EPS:
-1.56
Net Cash Flow:
$-27.63M
1W Performance:
+1.33%
1M Performance:
-25.91%
6M Performance:
+135.60%
1Y Performance:
+262.92%
1-Day Range:
$20.77
$23.36
1-Week Range:
$20.77
$23.36
52-Week Range:
$6.115
$34.84
Caredx Inc Stock (CDNA) Company Profile
Name
Caredx Inc
Sector
Industry
Phone
415-287-2300
Address
8000 MARINA BLVD, BRISBANE, CA
Caredx Inc Stock (CDNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-09-23 | Upgrade | Stephens | Equal-Weight → Overweight |
| Aug-15-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-11-23 | Downgrade | BTIG Research | Buy → Neutral |
| Mar-07-23 | Downgrade | Stephens | Overweight → Equal-Weight |
| Mar-03-23 | Downgrade | Craig Hallum | Buy → Hold |
| Mar-03-23 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Apr-25-22 | Initiated | Stephens | Overweight |
| Jul-20-21 | Resumed | BTIG Research | Buy |
| Jun-03-21 | Initiated | Goldman | Buy |
| Feb-26-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-30-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-08-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-02-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-26-20 | Initiated | BTIG Research | Buy |
| Jun-19-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-01-19 | Resumed | Craig Hallum | Buy |
| May-09-19 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-15-19 | Initiated | Jefferies | Buy |
| Oct-23-18 | Resumed | Raymond James | Strong Buy |
| Sep-18-18 | Reiterated | H.C. Wainwright | Neutral |
| Nov-27-17 | Initiated | H.C. Wainwright | Buy |
| Jun-14-16 | Reiterated | Mizuho | Buy |
| Sep-29-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-25-15 | Initiated | Craig Hallum | Buy |
| Mar-18-15 | Reiterated | Mizuho | Buy |
View All
Caredx Inc Stock (CDNA) Latest News
CareDx (NASDAQ:CDNA) Shares Gap Down Following Analyst Downgrade - MarketBeat
CareDx (NASDAQ:CDNA) Price Target Lowered to $35.00 at BTIG Research - MarketBeat
CareDx (NASDAQ:CDNA) Issues Earnings Results, Beats Expectations By $0.11 EPS - MarketBeat
Sumitomo Mitsui Trust Group's Strategic Reduction in CareDx Inc Holdings - GuruFocus.com
Earnings call: CareDx sees robust growth in Q3, raises FY 2024 outlook - Investing.com
CareDx price target lowered to $35 from $40 at BTIG - TipRanks
The Market Doesn't Like What It Sees From CareDx, Inc's (NASDAQ:CDNA) Revenues Yet As Shares Tumble 26% - Simply Wall St
CareDx stock dips 20%, BTIG sees value with revenue growth set to accelerate in 2025 - Investing.com
CareDx Inc (CDNA) Q3 2024 Earnings Call Highlights: Robust Reven - GuruFocus.com
CareDx Inc (CDNA) Q3 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic ... - Yahoo Finance
CareDx Inc. Reports Solid Growth and Raises Guidance - TipRanks
Caredx Inc earnings beat by $0.39, revenue topped estimates - Investing.com
CareDx: Q3 Earnings Snapshot - San Antonio Express-News
CareDx Reports Third Quarter 2024 Results and Raises Revenue Guidance - The Bakersfield Californian
CareDx (CDNA) Set to Announce Earnings on Monday - Defense World
Assenagon Asset Management S.A. Sells 100,518 Shares of CareDx, Inc (NASDAQ:CDNA) - MarketBeat
Jing Huang Joins CareDx as Chief Data and AI Officer - MPO-mag
CareDx (CDNA) Scheduled to Post Quarterly Earnings on Monday - MarketBeat
CareDx, Inc (NASDAQ:CDNA) Shares Acquired by Allspring Global Investments Holdings LLC - MarketBeat
CAREDX INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc.CDNA - AccessWire
HC Wainwright Issues Positive Outlook for CareDx Earnings - MarketBeat
CareDx and Dovetail Genomics announce HLA typing partnershi - Investing.com
CareDx and Dovetail Genomics announce HLA typing partnershi By Investing.com - Investing.com Australia
CareDx and Dovetail Genomics Announce Strategic Partnership to Drive Next Wave of Innovation in Transplant Matching with Cutting-Edge Hi-C Technology - The Bakersfield Californian
CareDx (NASDAQ:CDNA) Receives “Neutral” Rating from HC Wainwright - Defense World
H.C. Wainwright retains Hold rating on CareDx shares after Q3 revenue beat - Investing.com Australia
Analysts Set CareDx, Inc (NASDAQ:CDNA) PT at $30.60 - MarketBeat
CareDx, Inc (NASDAQ:CDNA) Given Consensus Recommendation of “Hold” by Analysts - Defense World
A Closer Look at 5 Analyst Recommendations For CareDx - Benzinga
CareDx (NASDAQ:CDNA) Earns "Neutral" Rating from HC Wainwright - MarketBeat
500: Something went wrong - Investing.com UK
CareDx Showcases Latest Advancements Across its HLA Typing Solutions at Annual American Society for Histocompatibility and Immunogenetics Meeting - Business Wire
CareDx, JD.com And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - MSN
CareDx (NASDAQ:CDNA) Stock Rating Upgraded by StockNews.com - Defense World
Exchange Traded Concepts LLC Sells 24,064 Shares of CareDx, Inc (NASDAQ:CDNA) - MarketBeat
CareDx (NASDAQ:CDNA) Upgraded to "Buy" at StockNews.com - MarketBeat
State Street Corp's Strategic Reduction in CareDx Inc Holdings - GuruFocus.com
CareDx (NASDAQ:CDNA) Trading Down 3.5%Here's What Happened - MarketBeat
CareDx Inc (CDNA) Trading Down 4.14% on Oct 16 - GuruFocus.com
5 Analysts Assess CareDx: What You Need To Know - Benzinga
CareDx (NASDAQ:CDNA) Price Target Raised to $35.00 - MarketBeat
CareDx Reports Strong Q3 2024 Revenue Growth - Yahoo Finance
CareDx (NASDAQ:CDNA) Shares Gap DownShould You Sell? - MarketBeat
Top investors say Caredx Inc (CDNA) ticks everything they need - SETE News
CareDx Reports Preliminary Financial Results for Third Quarter 2024 - Business Wire
SG Americas Securities LLC Has $574,000 Stock Position in CareDx, Inc (NASDAQ:CDNA) - MarketBeat
Analysts review Caredx Inc’s rating - Knox Daily
Financial Metrics Unveiled: Caredx Inc (CDNA)’s Key Ratios in the Spotlight - The Dwinnex
Technical analysis of Caredx Inc (CDNA) stock chart patterns - US Post News
CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)October 11, 2024 - BioSpace
CareDx stock climbs 7% amid reports Natera not pursuing litigation - MSN
Caredx Inc Stock (CDNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Caredx Inc Stock (CDNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Johnson Alexander L | See Remarks |
Aug 21 '24 |
Option Exercise |
23.48 |
21,557 |
506,158 |
306,540 |
| Johnson Alexander L | See Remarks |
Aug 20 '24 |
Sale |
33.17 |
39,466 |
1,309,087 |
284,983 |
| Johnson Alexander L | See Remarks |
Aug 21 '24 |
Sale |
32.58 |
21,557 |
702,327 |
284,983 |
| Maag Peter | Director |
Aug 20 '24 |
Option Exercise |
7.96 |
26,708 |
212,596 |
365,576 |
| Maag Peter | Director |
Aug 20 '24 |
Sale |
33.04 |
35,552 |
1,174,493 |
330,024 |
| Johnson Alexander L | See Remarks |
Aug 19 '24 |
Sale |
33.55 |
34,231 |
1,148,335 |
284,983 |
3.48%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):